Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B

Background/Aims Long-term data on antiviral therapy in Korean patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are limited. This study evaluated the efficacy and safety of entecavir (ETV) and lamivudine (LAM) over 240 weeks. Methods Treatment-naive patients with HBeAg-n...

Full description

Bibliographic Details
Main Authors: Kwan Sik Lee, Young-Oh Kweon, Soon-Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon-Ju Lee, Dong Joon Kim, Tae Hun Kim, Young-Sok Lee, Kwan Soo Byun, Daeghon Kim, Myung Seok Lee, Kyungha Yu, Dong Jin Suh
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2017-12-01
Series:Clinical and Molecular Hepatology
Subjects:
Hepatitis B
Entecavir
Long-term effects
Lamivudine
Online Access:http://e-cmh.org/upload/pdf/cmh-2016-0040.pdf

Internet

http://e-cmh.org/upload/pdf/cmh-2016-0040.pdf

Similar Items